Molecular Companions AG (MOLN) Discusses Scientific Imaging and Dosimetry Information for DLL3 Focusing on Radiotherapeutic MPO712 Transcript

FollowPlay Earnings CallPlay Earnings Call

Molecular Partners AG (MOLN) Discusses Clinical Imaging and Dosimetry Data for DLL3 Targeting Radiotherapeutic MPO712 February 2, 2026 8:00 AM EST

Company Participants

Seth Lewis – Senior Vice President of Investor Relations, Communications & Strategy
Patrick Amstutz – Co-Founder, CEO, Member of Management Board & Director
Michael Stumpp – Co-Founder, Executive VP of Projects & Member of Management Board
Philippe Legenne – Chief Medical Officer & Member of the Management Board

Conference Call Participants

Ken Herrmann
Yue-Wen Zhu – LifeSci Capital, LLC, Research Division
Chiara Montironi – Kempen & Co. NV, Research Division
William Maughan – Clear Street LLC., Research Division
Michael Nedelcovych – TD Cowen, Research Division
Joris Zimmermann – Octavian AG, Research Division

Presentation

Operator

Good day, and welcome to the Molecular Partners call and webcast. (Operator Instructions) As a reminder, this call may be recorded. I would now like to turn the call over to Seth Lewis, Head of Investor Relations and Strategy. Please go ahead.

Seth Lewis
Senior Vice President of Investor Relations, Communications & Strategy

Thank you and welcome to today’s call. My name is Seth Lewis, Head of Investor Relations and Strategy. And this morning, we’re following up on the data presented this weekend at the Theranostics World Conference in South Africa for MP0712, our DLL3 targeting radiotherapeutic. This data reflects clinical imaging and dosimetry data that was conducted as part of a named patient access program under the legal framework for compassionate care in South Africa, also referred to as Section 21 of the Medicines and Related Substances Act.

This was done under the supervision of Dr. Mike Sathekge, Professor and Head of Nuclear Medicine at University of Pretoria and Steve Biko Academic Hospital and President and CEO of Nuclear Medicine Research Infrastructure, or NuMeRI.

We will start today’s call with several prepared slides and then open up for

Source link